0453 GMT - Citi analyst Mathieu Chevrier would like more details on Ebos's acquisition of pet-medicine provider SVS. Chevrier tells clients in a note that the acquisition is in line with the pharmaceuticals supplier's long-standing M&A strategy, but that the New Zealand-based company didn't provide information on anticipated synergies, capital intensity or how SVS performed prior to the Covid-driven surge in pet ownership. Chevrier expects SVS, combined with Ebos's acquisition of the remaining 10% stake in its Transmedic unit, to be 1%-2% accretive to his fiscal 2026 EPS estimate. Citi has a sell rating and A$32.00 target price on Ebos's Australia-listed stock, which is down 5.1% at A$33.74. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
April 11, 2025 00:53 ET (04:53 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.